Molecular Biology of Urological Cancers

Dear Colleagues,

The three main urological cancers are prostate, bladder, and kidney cancers. They represent 2.2 million cases and 735,000 deaths per year worldwide. At the metastatic stage, although considerable efforts are made, including the development of immune checkpoint inhibitors, therapies remain too rarely curative. This is mainly due to resistance, either intrinsic or therapy-induced, and heterogeneity, which is particularly strong in kidney and bladder cancers, between patients, and for the same patient at histopathologic, genetic, and molecular levels. Resistance to current therapies is also observed for prostate cancer, for which second-generation hormonotherapy and PARP inhibitors are now used as first-line therapies. There have been substantial advances in cutting-edge molecular profiling approaches, including next-generation sequencing and bioinformatic analysis, which have allowed clinicians and researchers in the field to analyze tumor biology in more detail and stratify patients using factors linked with clinical outcome and response to therapy. Landmark advances have been made in recent years with the arrival of drug conjugates and targeted therapies. These are potential molecular characteristics of these cancers. This Special Issue intends to make an exhaustive inventory of the molecular biology of the main urological cancers, considering both the molecular mechanisms of cancer development and the mechanisms of therapeutic responses and resistances.

Dr. Philippe Barthélémy
Dr. Thierry Massfelder
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• kidney cancer
• prostate cancer
• bladder cancer
• therapies
• cell signaling
• resistance
• gene profiling
• hypoxia
• metabolism